Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models.
Conage-Pough JE, Stopka SA, Oh JH, Mladek AC, Burgenske DM, Regan MS, Baquer G, Decker PA, Carlson BL, Bakken KK, Zhang J, Liu L, Sun C, Mu Z, Zhong W, Tran NL, Elmquist WF, Agar NYR, Sarkaria JN, White FM. Conage-Pough JE, et al. Among authors: burgenske dm. Neurooncol Adv. 2023 May 27;5(1):vdad066. doi: 10.1093/noajnl/vdad066. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37324218 Free PMC article.
Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors.
Jackson CB, Noorbakhsh SI, Sundaram RK, Kalathil AN, Ganesa S, Jia L, Breslin H, Burgenske DM, Gilad O, Sarkaria JN, Bindra RS. Jackson CB, et al. Among authors: burgenske dm. Cancer Res. 2019 Sep 1;79(17):4331-4338. doi: 10.1158/0008-5472.CAN-18-3394. Epub 2019 Jul 4. Cancer Res. 2019. PMID: 31273061 Free PMC article.
Molecular profiling of long-term IDH-wildtype glioblastoma survivors.
Burgenske DM, Yang J, Decker PA, Kollmeyer TM, Kosel ML, Mladek AC, Caron AA, Vaubel RA, Gupta SK, Kitange GJ, Sicotte H, Youland RS, Remonde D, Voss JS, Fritcher EGB, Kolsky KL, Ida CM, Meyer FB, Lachance DH, Parney IJ, Kipp BR, Giannini C, Sulman EP, Jenkins RB, Eckel-Passow JE, Sarkaria JN. Burgenske DM, et al. Neuro Oncol. 2019 Nov 4;21(11):1458-1469. doi: 10.1093/neuonc/noz129. Neuro Oncol. 2019. PMID: 31346613 Free PMC article. Clinical Trial.
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.
Marin BM, Porath KA, Jain S, Kim M, Conage-Pough JE, Oh JH, Miller CL, Talele S, Kitange GJ, Tian S, Burgenske DM, Mladek AC, Gupta SK, Decker PA, McMinn MH, Stopka SA, Regan MS, He L, Carlson BL, Bakken K, Burns TC, Parney IF, Giannini C, Agar NYR, Eckel-Passow JE, Cochran JR, Elmquist WF, Vaubel RA, White FM, Sarkaria JN. Marin BM, et al. Among authors: burgenske dm. Neuro Oncol. 2021 Dec 1;23(12):2042-2053. doi: 10.1093/neuonc/noab133. Neuro Oncol. 2021. PMID: 34050676 Free PMC article.
Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.
Burgenske DM, Talele S, Pokorny JL, Mladek AC, Bakken KK, Carlson BL, Schroeder MA, He L, Hu Z, Gampa G, Kosel ML, Decker PA, Kitange GJ, Schmitt-Hoffmann A, Bachmann F, Vaubel RA, Eckel-Passow JE, Giannini C, McSheehy P, Lane HA, Elmquist WF, Sarkaria JN. Burgenske DM, et al. Neuro Oncol. 2022 Mar 12;24(3):384-395. doi: 10.1093/neuonc/noab162. Neuro Oncol. 2022. PMID: 34232318 Free PMC article.
21 results